Deep Brain Stimulation in Early-Stage Parkinson's Disease: Patient Experience after 11 Years

• Published in: Brain sciences Vol. 12; no. 6; p. 766
• Main Authors: Stoehr, Kaitlyn, Pazira, Kian, Bonnet, Kemberlee, Schlundt, David, Charles, David, Hacker, Mallory
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 11.06.2022; MDPI
• Subjects: Clinical trials; Coping; Deep brain stimulation; Drug therapy; Dyskinesia; Early experience; Enrollments; Informed consent; Interviews; Movement disorders; Neurodegenerative diseases; Parkinson's disease; patient experience; Patients; Qualitative research; Quality of life; clinical trials; qualitative research; patient experience; Parkinson’s disease; deep brain stimulation
• ISSN: 2076-3425; 2076-3425
• DOI: 10.3390/brainsci12060766

The deep brain stimulation (DBS) in early-stage Parkinson's disease (PD) pilot trial began more than a decade ago and remains the only investigation of DBS in mildly symptomatic patients. Patients completed therapeutic washouts biannually for two years, outpatient assessments through five years, and a longitudinal washout assessment after 11 years. Here, the patient experience of participating in the early DBS pilot trial is described. Semi-structured interviews were audio-recorded and transcribed. Transcripts were coded, analyzed using an iterative inductive-deductive approach, and used to develop a conceptual framework. Ten participants (n = 6 early optimal drug therapy (ODT), n = 4 early DBS + ODT) were interviewed. Motivations for participation included benefit to future PD patients and potential personal benefit, while hesitations included risk of surgical complications. While early ODT patients who received standard-of-care DBS described significant changes in their functional capacities after surgery, early DBS patients described a maintenance of quality of life that made PD less impactful over an extended period. Patients expressed high satisfaction with trial participation and early DBS. This study suggests that the PD experience with early DBS may notably differ from standard-of-care DBS. The FDA has approved the conduct of a pivotal clinical trial evaluating DBS in early-stage PD (IDEG050016).